Abexinostat Shows Promise for B Cell Lymphoma
Abexinostat, a novel pan-histone deacetylase inhibitor, is emerging as a promising therapeutic agent for patients with relapsed or refractory B ...
Abexinostat, a novel pan-histone deacetylase inhibitor, is emerging as a promising therapeutic agent for patients with relapsed or refractory B ...
In a groundbreaking study recently published in BMC Cancer, researchers have unveiled significant abnormalities in the proportions and functional dynamics ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine